Tezepelumab in real-world CRSwNP: a real-world look at patient outcomes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

PETRICHOR is a prospective, non-interventional, single-arm study conducted at multiple centers in Germany to observe real-world outcomes in adults with severe CRSwNP who start tezepelumab as part of standard care. No additional procedures are required beyond routine visits, and data are gathered from baseline through up to 104 weeks using epidemiological methods. Participants, their doctors, and the study team make treatment decisions together, independent of enrollment. The study collects clinical and patient-reported outcomes during standard care visits and uses active patient-reported outcome collection via an app or paper as needed. This design aims to reflect everyday practice rather than a controlled trial setting.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* \- Participant must be 18 years of age or older, at the time of signing the informed consent.
* \- Confirmed diagnosis of CRSwNP for at least 12 months prior to routine care visit 1.
* \- Stable standard of care (SoC) treatment with Intranasal corticosteroids (INCS) for CRSwNP for at least 30 days prior to routine care visit 1.
* \- Physician decision that participant is eligible for treatment with Tezepelumab according to locally approved CRSwNP label.
* Participants must be able and willing to read and comprehend written instructions, to collect Patient-reported outcome (PROs) and medication intake via app or alternative mode (paper) and to sign the informed consent document. Use of the mobile app is optional; participants without smartphones will not be excluded. Mode of data capture will be recorded and adjusted for in analyses where relevant.
* \- Participants who will be enrolled after index date need to have at least one measurement for SNOT-22 prior (within a maximum of 4 weeks) to index date.
* \- -

Exclusion Criteria:

* \- Participants who participate in an observational study that might influence the assessment of the current study (participants can be part of the German National Registry for Chronic rhinosinusitis (GENRE-CRS)); or participate in an interventional clinical trial in the last 3 months.
* \- Concurrent biologic therapy for CRSwNP or Asthma except where the last dose was administered ≥ 30 days. Stable allergen immunotherapy (defined as a stable dose and regimen at the time of enrolment) is allowed.
* \- Endoscopic NP surgery within 6 months prior to index date.
* \- Condition (acute or chronic) that, in the investigator's opinion, would limit the participant's ability to complete questionnaires or participate in this study.
* \- History of documented anaphylactic reactions/hypersensitivity/serious allergic reactions (immune complex disease) following any biologic therapy.
* \- Known hypersensitivity to Tezepelumab or any of its excipients.
* \- Pregnancy, planned pregnancy or lactation period.
* \- -

Where it's running

• Research Site
  Berlin, Germany Recruiting
• Research Site
  Bochum, Germany Recruiting
• Research Site
  Braunschweig, Germany Recruiting
• Research Site
  Dortmund, Germany Recruiting
• Research Site
  Dresden, Germany Recruiting
• Research Site
  Erfurt, Germany Recruiting

Study contacts

• Study coordinator: AstraZeneca Clinical Study Information Center
• Email: information.center@astrazeneca.com
• Phone: 1-877-240-9479

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Real-world use of tezepelumab for chronic rhinosinusitis with nasal polyps in Russia

  This study will see how tezepelumab works in adults in Russia who have chronic rhinosinusitis with nasal polyps, with or without asthma.

  Recruiting at 10 sites AstraZeneca · Kazan' and 9 other locations · NCT07399665

• Metabolic and Immunologic Biomarkers in Chronic Rhinosinusitis with Nasal Polyps

  This study tests whether metabolic and immune markers in nasal tissue and blood differ between people with nasal polyps and those without, to help understand CRSwNP and find potential diagnostic clues.

  Recruiting Harran University · Sanliurfa, Şanlıurfa · NCT07860411

• Structured physical activity program added to tezepelumab for adults with severe asthma

  A 12-week program to help adults with severe asthma who start tezepelumab see if adding guided physical activity improves activity levels and chances of remission.

  Recruiting University of Leeds · Leeds · NCT07735494

• Tezepelumab for Chinese adults with nasal polyps: a 24-week treatment study

  This trial tests whether tezepelumab can improve nasal polyps and symptoms in Chinese adults with chronic rhinosinusitis with nasal polyps who are starting therapy.

  Recruiting at 34 sites Phase 3 AstraZeneca · Beijing and 33 other locations · NCT07520162

• BBT002 in healthy adults and in people with chronic rhinosinusitis with nasal polyps

  This study tests BBT002 versus placebo to see how it acts, how safe it is, and whether it helps people with chronic rhinosinusitis with nasal polyps, with or without asthma.

  Recruiting at 12 sites Phase 1/2 Bambusa Therapeutics · Beijing, Beijing Municipality and 11 other locations · NCT07436949

• Tezepelumab to reduce maintenance medication in people with severe asthma

  This will test whether people aged 12–80 with severe asthma in China who start tezepelumab can safely reduce their regular maintenance medicines while keeping asthma controlled.

  Recruiting at 59 sites Phase 3 AstraZeneca · Beijing and 74 other locations · NCT07363642

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.